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Safety of infusing rituximab at a more rapid rate
in patients with rheumatoid arthritis: results from
the RATE-RA study
Charles H Pritchard1*, Maria W Greenwald2, Joel M Kremer3, Norman B Gaylis4, William Rigby5, Steve Zlotnick6,
Carol Chung6, Birgit Jaber7, William Reiss6 and the RATE-RA Study Group

Abstract
Background: As recommended in the current prescribing information, rituximab infusions in patients with
rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a
burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster
rate for an infusion period of 2 hours in patients with RA.
Methods: Patients with an inadequate response to anti-TNF who were rituximab-naive or -experienced received 2
courses of rituximab: Infusion 1 (Day 1) was administered over the standard 4.25 hours, and Infusions 2 (Day 15), 3
(Day 168) and 4 (Day 182) were administered over a faster 2-hour period. The primary endpoint was incidence of
infusion-related reactions (IRRs) associated with Infusion 2.
Results: Of the 351 patients enrolled, 87% and 13% were rituximab-naive and -experienced, respectively. The
incidence (95% CI) of IRRs associated with Infusion 1 was 16.2% (12.5%, 20.5%) and consistent with weighted
historical incidence of 20.7% (19.4%, 22.1%). The incidence (95% CI) of IRRs associated with Infusions 2, 3, and 4
compared with respective weighted historical incidences at the standard infusion rate was 6.5% (4.1%, 9.7%) vs
8.1% (7.2%, 9.1%); 5.9% (3.5%, 9.3%) vs 11.5% (10.3%, 12.8%); and 0.7 (0.1%, 2.6%) vs 5.0% (4.2%, 6.0%), respectively.
All IRRs were grade 1 or 2, except for 3 grade 3 IRRs associated with Infusion 1 and 2 grade 3 IRRs associated with
Infusion 2. Four patients experienced a total of 5 grade 3 IRRs; 3 of these patients continued on to received
subsequent infusions at the faster rate. There were no serious IRRs.
Conclusion: This study demonstrated that rituximab can be administered at the faster infusion rate at the second
and subsequent infusions without increasing the rate or severity of IRRs.
Keywords: Rituximab, Rheumatoid arthritis, Infusion-related reactions, Adverse events

Background
Rituximab, a chimeric monoclonal antibody that binds to
the antigen CD20, is approved worldwide in combination
with methotrexate (MTX) for the treatment of moderately
to severely active rheumatoid arthritis (RA) in patients
with an inadequate response to at least one tumor necrosis factor (TNF)-α inhibitors. In clinical studies, rituximab has been shown to improve the signs and
symptoms of disease [1] and reduce the rate of joint
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1
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Full list of author information is available at the end of the article

damage progression [2], with sustained efficacy at 1 year
upon retreatment [1,3,4].
The indicated dose of rituximab for the treatment of RA
is two 1000-mg intravenous (IV) infusions separated by
2 weeks every 24 weeks or based on clinical evaluation,
but not sooner than every 16 weeks. As recommended in
the current prescribing information, rituximab infusions
take 4.25 hours for the first infusion and 3.25 hours for
the second and subsequent infusions [5].
The infusion regimen as currently recommended was
based on the rituximab dosing regimen used to treat patients with non-Hodgkin’s lymphoma (NHL). The mechanism by which rituximab elicits infusion-related reactions
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(IRRs) is not well understood; however, there is evidence
that symptoms may be associated with the release of
inflammatory cytokines as a result of rituximab binding
to CD20 on B cells and cell lysis [6,7]. Because patients
with RA have a lower peripheral B cell burden at baseline compared with patients with lymphoma, this may
partially explain why the incidence of IRRs reported in
RA is lower than that in NHL [5].
The safety profile of rituximab has been documented
in numerous clinical trials. IRRs are the most commonly
reported adverse reaction with the majority occurring at
the first infusion of the first course. In previously published randomized controlled trials of rituximab in RA,
IRRs have been defined as an adverse event (AE) occurring
during or within 24 hours of an infusion [5,8]. As reported
by van Vollenhoven and colleagues in a pooled analysis of
all-exposure patient (N = 3194) data from the RA global
clinical trial program, the rate of IRRs was 23.0% during
the first infusion of the first course and decreased with
each subsequent infusion. Most IRRs were mild to moderate (grade 1 and 2) and rarely serious (0.5%) [8].
The burden of the rituximab standard infusion protocol on the health care system is not insignificant. Longer
infusion times and frequent infusion rate changes result
in longer observation times, increased nursing and administration staff workloads, and pose a temporal inconvenience to patients. Based on the success of rapid infusion
protocols in the oncology setting [9,10], several studies
have evaluated the practicality of accelerated rituximab infusion rates in patients with RA and found them to be safe
and tolerable; however, these results are restricted by small
study sizes and limited clinical details [11-16].
The objective of this prospective, multicenter study
was to evaluate the safety of infusing rituximab at a faster
rate for an infusion period of 2 hours.

Methods
RATE-RA was a 30-week, prospective, multicenter, openlabel, single-arm study conducted in 74 sites across the
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United States. Between July 26, 2011, and June 8, 2012,
patients with moderately to severely active RA who had
an inadequate response to at least 1 anti-TNF agent and
were receiving concomitant MTX were enrolled.
Patients were eligible if they were ≥ 18 years of age,
had RA for ≥ 6 months, and were either rituximab-naive
or -experienced (defined as having received no more than
2 courses of rituximab 6 to 9 months prior to baseline,
with each course consisting of 2 infusions of 1000 mg
each). Use of MTX 10 to 25 mg/week (oral or parenteral)
for at least 8 weeks prior to baseline was required, and
concomitant corticosteroids (≤10 mg prednisone or
equivalent) were allowed. Key exclusion criteria included
a history of rheumatic autoimmune disease other than RA
or secondary Sjögren syndrome; history of severe allergic
or anaphylactic reactions to monoclonal antibodies; previous serious IRRs to any biologic therapy; grade 3/4 New
York Heart Association congestive heart failure; history of
significant arrhythmia; and evidence of serious uncontrolled hypertension.
This study was performed in accordance with the
Declaration of Helsinki. The study was approved by the
Copernicus Group Independent Review Board at all but
four investigator sites, which received approval from their
local governing institutional review board (DartmouthHitchcock Medical Center – Committee for the Protection
of Human Subjects; North Mississippi Health Services;
Sutter Health and Western Institutional Review Board). All
patients provided written informed consent (RATE-RA
ClinicalTrials.gov identifier NCT01382940).
Study design

The study design is summarized in Figure 1. Patients
received 2 courses of rituximab 24 weeks apart, with
each course consisting of two 1000-mg IV infusions of
rituximab separated by 2 weeks. The first infusion was
administered over the standard 4.25 hours while subsequent infusions were administered at faster rates for a
2-hour period. Infusion 1 (Day 1) was initiated at a rate

Screening

Primary endpoint:
IRRs during or 24 h after Infusion 2

Day 1

Day 15

Day 168

Infusion 2
1000 mg, 2 h

Infusion 3
1000 mg, 2 h

Infusion 1
1000 mg, 4.25 h

Figure 1 Study design.

End of study:
4 weeks after Infusion 4

Day 182

Infusion 4
1000 mg, 2 h
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of 50 mg/hour (Table 1). In the absence of infusion toxicity, the infusion rate was increased by 50 mg/hour increments every 30 minutes, to a maximum of 400 mg/hour.
The total estimated time to complete a 1000-mg dose was
4 hours, 15 minutes (4.25 hours). For Infusions 2 (Day 15),
3 (Day 168) and 4 (Day 182), rituximab (1000 mg in
250 mL normal saline) was initiated at 250 mg/hour
(Table 1). After 30 minutes, the rate was escalated to a rate
of 600 mg/hour for the next 90 minutes. The total estimated time to complete a 1000-mg dose based on this
rapid infusion schedule was just under 2 hours.
Premedication with 100 mg intravenous methylprednisolone, as well as 1 g acetaminophen and an antihistamine
(diphenhydramine HCL 50 mg or equivalent dose of alternate) were administered orally 30 to 60 minutes prior to
each rituximab infusion. Patients continued to receive
MTX as prescribed by their treating physicians. Changes
to MTX dose were allowed as long as the dose remained
within 10 to 25 mg/week.
The following information was collected at each infusion: the initial infusion rate, the number and proportion
of patients with an infusion modification and the reasons
for modification; the number and proportion of patients
who completed the 1000-mg dose; and the total infusion
times among those who completed the 1000-mg dose.
Safety assessments

All event incidences were calculated as per-patient incidences, defined as the proportion of patients experiencing
Table 1 Infusion schedule
Time (min)

Infusion rate
(mg/h) (mL/h)

Dose in 30 minutes Cumulative dose
(mg)

(mg)

Infusion 1
0-30

50

12.5

25

25

31-60

100

25

50

75

61-90

150

37.5

75

150

91-120

200

50

100

250

121-150

250

62.5

125

375

151-180

300

75

150

525

181-210

350

87.5

175

700

211-240

400

100

200

900

241-255

400

100

200

1000

Infusion 2, 3 and 4
0-30

250

62.5

125

125

31-60

600

150

300

425

61-90

600

150

300

725

91 ≈ 120

600

150

275

1000

The total estimated time to complete a 1000-mg dose at Infusion 1 is 4 hours,
15 minutes (4.25 hours) with 8 infusion rate changes. The total estimated time
to complete a 1000-mg dose (1000 mg diluted in 250 mL of normal saline or
D5W) at Infusion 2, 3 and 4 is approximately 2 hours with 1 infusion
rate change.

the event. Multiple occurrences of a specific event for a
patient were counted once. The primary endpoint was
incidence of IRRs associated with Infusion 2. IRRs were
defined as AEs that occurred during or within 24 hours
of infusion. IRRs were identified based on a prespecified
list of 180 Medical Dictionary for Regulatory Activities
preferred terms, which has been used to analyze IRRs in
patients with RA across rituximab studies conducted by
Roche/Genentech. Secondary endpoints included incidence
of serious IRRs associated with Infusion 2, incidence of
IRRs and serious IRRs associated with Infusion 3, incidence
of National Cancer Institute Common Toxicity Criteria
(NCI-CTC) grade 3 or 4 AEs associated with Infusion 2
and 3, and incidence of stopping, slowing, or interrupting
Infusion 2 and 3.
Exploratory analyses evaluated the aforementioned endpoints that were associated with Infusion 1 and 4. Subgroup analyses by patients’ previous exposure to rituximab
were performed for all endpoints. Ad hoc analyses summarized the recurrence and severity of IRRs at subsequent
infusions by the maximum NCI-CTCAE grade of IRRs at
Infusions 1, 2, and 3.
Statistical methods

This study aimed to have at least 300 patients receive
the second rituximab infusion at a faster rate so that an
increase of at least 3% to 4% of IRRs from the weighted
reference incidence (8% to 9%, based on historical data
for rituximab) would be statistically significant. A study
size of 300 patients also provided 95% confidence to conclude that if there were no serious events, the incidence of
serious IRRs was < 1%.
Integrated data from rituximab clinical development
studies as of September 2012 were the basis for the
historical incidences of IRRs associated with rituximab
administration at the standard infusion rate. Incidences
of IRRs were compared against the weighted historical
incidences of IRRs, which were calculated using the historical incidences and adjusted for the proportion of patients
with 0, 1, or 2 courses of prior rituximab to account for
patients with prior rituximab who were more likely to
have a lower IRR incidence.
Study data were summarized using descriptive statistics.
The number and proportion of patients who experienced
the respective endpoints were provided with a 2-sided
95% exact CI of the proportion. For serious IRRs, a 1sided 95% exact confidence upper limit of the proportion
was provided.
Analysis populations

The safety evaluable population included all patients
who received rituximab during the study and had an assessment during or after the infusion. AEs that occurred
during the study were summarized based on the safety
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evaluable population. The faster infusion evaluable population included all patients who received Infusions 2, 3,
or 4 at the faster rate at the respective visits (Day 15,
168, or 182, respectively). Patients were classified as
having received a faster rate infusion for that visit if the
infusion was completed within 2.5 hours or the infusion
was not completed within 2.5 hours but started within
33% of the protocol-specified rate of 250 mg/hour
(>167.5 mg/hour).
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naive and -experienced demonstrated similar baseline
demographics (data not shown); however, rituximabnaive patients had a shorter mean disease duration by
2.4 years (12.2 ± 9.5 years vs 14.6 ± 11.1 years). Rituximabnaive patients demonstrated significantly higher mean
CD19 counts compared with rituximab-experienced
patients (252.6 ± 206.4 vs 47.9 ± 80.3 cells/μL); approximately 10% (31/306) and 82% (37/45) of rituximab-naive
and -experienced patients, respectively, had CD19 counts
below the lower limit of normal (<80 cells/μL).

Results
Patient disposition

Exposure to rituximab

The patient disposition is outlined in Figure 2. The number of withdrawals was consistent with that of previous
trials of similar duration [1]. A total of 351 patients received ≥ 1 infusion of rituximab (safety evaluable population). Of the 341 patients who received Infusion 2, 337
patients were included in the faster infusion evaluable
population. Four patients were excluded because infusion volume was not recorded. Of the 290 patients who
received Infusion 3, 289 were included in the faster infusion evaluable population. One patient was excluded
because the standard rate was used. All 278 patients
who received Infusion 4 were included in the faster infusion evaluable population.

Table 3 summarizes the total exposure to rituximab during the study and rituximab infusion duration by visit.
Thirteen of the 351 patients who received Infusion 1 did
not complete the 1000-mg infusion. The reasons included
no medication volume recorded (n = 4), treatment modifications due to non-serious AEs (n = 7), medication error
(n = 1), and an unknown reason (n = 1). The mean infusion time for Infusion 1 was 4.4 ± 0.3 hours, and approximately 12% (41/338) of patients receiving rituximab
1000 mg at Infusion 1 required more than 4.5 hours of
infusion time.
Four of the 337 patients who received Infusion 2 at
the faster rate did not complete the full 1000-mg infusion due to non-serious AEs (n = 3) and an unknown
reason (n = 1). One of the 289 patients who received Infusion 3 at the faster rate and 1 of the 278 patients who
received Infusion 4 at the faster rate did not complete
the full 1000-mg infusion due to a nonserious AE. The
mean infusion times for Infusion 2, 3, and 4 were 2.0 ± 0.1,
2.1 ± 0.3, and 2.0 ± 0.1 hours, respectively. A small proportion of patients who received the full 1000-mg dose at
Infusion 2 and 3 at the faster rate required more than
2.5 hours (1.5% [5/333] and 4.2% [12/288], respectively).

Baseline demographics and clinical characteristics

The baseline demographics and clinical characteristics of
the 337 patients in the faster infusion evaluable population were similar to the overall 351 patients in the
safety evaluable population (Table 2). The mean duration of disease was approximately 12.5 years, and 50%
had RA for more than 10 years. Approximately 87%
(306/351) were rituximab-naive and 13% (45/351) were
rituximab-experienced. Patients who were rituximab-

n = 351 enrolled
(74 US sites)

Safety evaluable
population

n = 351 received Infusion 1

n = 341 received Infusion 2
(n = 337 at the faster rate)

Faster infusion
evaluable population

n = 10 withdrew
•
•
•

n = 7 AE (4 with IRR)
n = 1 Lost to follow-up
n = 2 Subject’s decision

n = 51 withdrew
•
•
•
•
•

n = 10
n=3
n=7
n = 15
n = 16

AE (2 with IRR)
Lost to follow-up
Physician’s decision
Protocol violation
Subject’s decision

n = 290 received Infusion 3
(n = 289 at the faster rate)
n = 12 withdrew
n = 278 received Infusion 4
(n = 278 at the faster rate)

Figure 2 Patient disposition. IRR, infusion-related reaction.

•
•
•

n = 2 AE (0 IRR)
n = 5 Protocol violation
n = 5 Subject’s decision
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Table 2 Baseline demographics and clinical characteristics
Safety population
(n = 351)

Faster infusion evaluable populationa
(n = 337)

Demographics
Female, n (%)

279 (79.5)

268 (79.5)

Age, mean (SD), y

55.5 (11.5)

55.6 (11.4)

23-88

23-88

Range
Age group, n (%)
18-40 y

38 (10.8)

34 (10.1)

41-64 y

244 (69.5)

236 (70.0)

≥ 65 y

69 (19.7)

67 (19.9)

White

295 (84.0)

283 (84.0)

African American

35 (10.0)

33 (9.8)

Race, n (%)

Other
Weight, mean (SD), kg
Range
Height, mean (SD), cm
Range

21 (6.0)

21 (6.2)

84.9 (21.2)

84.9 (21.2)

47-156

47-156

165.0 (9.6)

165.0 (9.6)

130-198

130-198

RA clinical characteristics
Duration of RA, mean (SD), y

12.5 (9.7)

12.4 (9.6)

42 (12.0)

42 (12.5)

RA disease duration, n (%)
<3y
3-4 y

39 (11.1)

38 (11.3)

5-10 y

93 (26.5)

87 (25.8)

177 (50.4)

170 (50.4)

> 10 y

Prior rituximab treatment
No. of prior rituximab courses, n (%)
0

306 (87.2)

293 (86.9)

1

24 (6.8)

24 (7.1)

2

21 (6.0)

20 (5.9)

45

44

6.8 (0.9)

6.7 (0.9)

5-9

5-9

Months since most recent rituximab course, n
Mean (SD)
Range

Medication history
No. of prior anti-TNF agents, n (%)
0

4 (1.1)

4 (1.2)

1

187 (53.3)

182 (54.0)

2

116 (33.0)

108 (32.0)

≥3

44 (12.5)

43 (12.8)

Prior non–anti-TNF biologic DMARDs
Abatacept

17 (4.8)

16 (4.7)

Tocilizumab

12 (3.4)

12 (3.6)

17.4 (4.7)

17.3 (4.7)

Median (range)

17.5 (8–25)

17.5 (8–25)

Oral steroid use, n (%)

150 (42.7)

143 (42.4)

MTX dose, mg/wk
Mean (SD)

Pritchard et al. BMC Musculoskeletal Disorders 2014, 15:177
http://www.biomedcentral.com/1471-2474/15/177

Page 6 of 9

Table 2 Baseline demographics and clinical characteristics (Continued)
Oral steroid dose, mg/d
Mean (SD)

7.2 (3.4)

7.3 (3.4)

Median (range)

5 (2–25)

5 (2–25)

Anti-TNF, anti–tumor necrosis factor; DMARD, disease-modifying antirheumatic drug; IQR, interquartile range; MTX, methotrexate; RA, rheumatoid arthritis; SD,
standard deviation. aOf the 341 patients who received infusion 2, four were not included because medication volume was not recorded.

No patients receiving Infusion 4 required more than
2.5 hours of infusion time.

Safety findings

The incidence of IRRs during or within 24 hours of each
rituximab infusion is summarized in Figure 3. The proportion of patients who experienced IRRs decreased
consistently with each infusion, and was consistent with
or lower than historical clinical trial data. The incidence
of IRRs during or within Infusion 1 was 16.2% (95% CI,
12.5% to 20.5%) and similar to the weighted historical
incidence of 20.7% (95% CI, 19.4% to 22.1%). Of the 337
patients who received Infusion 2 at the faster rate, 22
patients (6.5% [95% CI, 4.1% to 9.7%]) experienced a
total of 30 IRRs, with nausea (1.2%) and chills (0.9%) being the most common events. This incidence was similar
to the weighted historical incidence of 8.1% (95% CI,
7.2% to 9.1%) at the standard infusion rate. The type and
severity of events were also similar to the reference
population. The incidence of IRRs for both Infusions 3
and 4 compared with the weighted historical incidences
were as follows: 5.9% (95% CI, 3.5% to 9.3%) vs 11.5%
(95% CI, 10.3% to 12.8%) for Infusion 3 and 0.7 (95% CI,
0.1% to 2.6%) vs 5.0% (95% CI, 4.2% to 6.0%) for Infusion
4. Ad hoc analyses showed no apparent trend between
the maximum grade of IRRs at the first, second, or third
infusion and the recurrence and grade of IRRs at subsequent infusions.

No serious IRRs or serious AEs (SAEs) were reported
during or within 24 hours of any infusion (Table 4). All
IRRs were CTC grade 1 or 2, except for 3 grade 3 IRRs
associated with Infusion 1 (Day 1) in 2 patients (eye irritation and urticaria in 1 patient, throat irritation in the
other patient) and 2 grade 3 IRRs associated with Infusion 2 (Day 15) (hypertension and headache in separate
patients). Of the 2 patients who experienced grade 3
IRRs associated with Infusion 1, one withdrew prior to
receiving Infusion 2; the other patient continued to receive the subsequent 3 infusions at the faster rate with
no IRRs except for a grade 2 IRR at Infusion 3. Both patients with a grade 3 IRR at Infusion 2 received Infusions
3 and 4 at a faster rate with no IRRs. There were no
grade 4 or fatal events. With a total of 904 rituximab
infusions administered in 340 patients at the faster rate
during Infusions 2, 3, and 4, the incidence of serious
IRRs or SAEs associated with rituximab infused at the
faster rate was < 0.9% (per-patient incidence) or < 0.33%
(per-infusion incidence).
A total of 221 patients (63%) experienced at least one
AE (inclusive of IRRs and other events) during the study.
AEs reported in > 2% of patients included headache
(5.7%), upper respiratory infection (5.4%), worsening RA
(5.1%), pruritus (4.3%), sinusitis (4.0%), urinary tract infection (3.7%), throat irritation (3.4%), arthralgia (3.1%),
nausea (3.1%), flushing (2.6%), cough (2.3%), dizziness
(2.3%), ear pruritus (2.3%), and rash (2.3%). A total of 33
SAEs were reported in 30 patients (8.5%) during the

Table 3 Exposure to rituximab during the study for all patients
Received infusion

Infusion 1

Infusion 2

Infusion 3

Infusion 4

351a

341a

290b

278

Infusion at the faster rate

NA

337

289

278

Completed 1000 mgc

338

333

288

277

338

333

288

277

Mean (SD)

4.4 (0.3)

2.0 (0.1)

2.1 (0.3)

2.0 (0.1)

Range

4.1-6.4

1.8-3.2

1.9-4.3

1.9-2.4

> 2.5 h

338 (100%)

5 (1.5%)

12 (4.2%)

0

> 4.5 h

41 (12.1%)

0

0

0

Total infusion hours
n

NA, not applicable; SD, standard deviation. aInfusion rate and dose could not be determined for 4 patients because the site failed to record the infusion volume.
Of these 4 patients, 3 at Day 168 and 2 at Day 182 received rituximab at the faster rate. bRituximab was administered at the standard infusion rate in 1 patient.
c
Rituximab dose was derived from the sum of the volume received at each segment. To account for truncation errors, the derived dose of 970 mg or larger was
considered as completed 1000 mg.
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% of patients experiencing IRRs

30

Historical referencea
RATE-RA

25
20.7

16.2

Primary
Endpoint

20

15

11.5
8.1

10

6.5

5.9
5.0

5

0.7

0
Infusion 1
(Day 1)
(n = 351)

Infusion 2
(Day 15)
(n = 337)

Labeled rate

Infusion 3
(Day 168)
(n = 289)

Infusion 4
(Day 182)
(n = 278)

Faster infusion rate

Figure 3 IRRs during or within 24 hours of each rituximab infusion. IRR, infusion-related reaction, RTX, rituximab. Error bars are 95% CI of the
percentage. aWeighted average of incidences reported in historical integrated data of phase 2 and phase 3 studies and open-label extension to
date, adjusted for the proportion of patients with 0, 1, or 2 courses of prior rituximab.

study, with a per-100 patient-year rate of 16.0 (95% CI,
11.3 to 22.4). Of the 33 SAEs, 3 (pneumonia, sepsis, and
septic shock) were considered by investigators to be related to rituximab treatment. Ten patients (2.8%) had a
total of 12 serious infectious events (defined as serious
infections or events treated with IV antibiotics) reported
during the study, with a per-100 patient-year rate of 5.8
(95% CI, 3.3 to 10.2). These rates are consistent with
what has been previously reported for rituximab in RA
[1,3]. There were no deaths in this study.
Subgroup analysis by prior rituximab experience

As expected, rituximab-naive patients had a higher incidence of IRRs compared with rituximab-experienced

patients at Infusion 1 (17.3% [95% CI, 13.3% to 22.0%]
vs 8.9% [95% CI, 2.5% to 21.2%], respectively). The incidence of IRRs was similar between rituximab-naive
and -experienced patients during or within 24 hours of
Infusion 2 (6.5% [95% CI, 3.9% to 9.9%] vs 6.8% [95% CI,
1.4% to 18.7%]), Infusion 3 (6.4% [95% CI, 3.7% to 10.1%]
vs 2.6% [95% CI, 0.1% to 13.8%]), and Infusion 4 (0.4%
[95% CI, 0.0% to 2.3] vs 2.9% [95% CI, 0.1% to 14.9%]).

Discussion
In this prospective, open-label study, the reported incidence of IRRs for the first rituximab infusion of course 1
was 16.2%. When rituximab was infused at a faster rate
over a 2-hour period during the second infusion of

Table 4 Events during or within 24 hours of each rituximab infusion
Infusion 1
(N = 351)
n (%)
(95% CI)a

Infusion 2
(N = 337)
n (%)
(95% CI)a

Infusion 3
(N = 289)
n (%)
(95% CI)a

Infusion 4
(N = 278)
n (%)
(95% CI)a

0 (0)
(− to 0.8)

0 (0)
(− to 0.9)

0 (0)
(− to 1.0)

0 (0)
(− to 1.1)

62 (17.7)
(13.8 to 22.1)

24 (7.1)
(4.6 to 10.4)

22 (7.6)
(4.8 to 11.3)

5 (1.8)
(0.6 to 4.1)

Serious AEs

0 (0)
(− to 0.8)

0 (0)
(− to 0.9)

0 (0)
(− to 1.0)

0 (0)
(− to 1.1)

CTC grade 3/4 AEs

2 (0.6)
(0.1 to 2.0)

2 (0.6)
(0.1 to 2.0)

0 (0)
(0.1 to 2.1)

0 (0)
(0.0 to 1.3)

Infusion stopped/slowed/interruptedb

43 (12.3)
(9.0 to 16.1)

13 (3.9)
(2.1 to 6.5)

19 (6.6)
(4.0 to 10.1)

3 (1.1)
(0.2 to 3.1)

Events
Serious IRRs
IRRs and other AEs

AE, adverse event; CTC, Common Terminology Criteria; IRRs, infusion-related reactions. aOne-sided CI for serious events. bDue to AE, medication error, or other
reason such as bathroom break.
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Course 1 and the first and second infusions of Course 2,
the incidence of IRRs was 6.5% (primary endpoint),
5.9%, and 0.7%, respectively. These observed incidences
were no greater than the weighted historical incidences
of IRRs when rituximab was infused at the standard rate,
demonstrating that rituximab can be administered at the
faster rate at the second and subsequent infusions without increasing the risk of IRRs in patients with RA. In
addition, the type and severity of IRRs were similar to
the reference population. There were no serious IRRs or
SAEs during or within 24 hours of any infusion during the
2 courses of treatment. Subgroup analysis indicated that
rates of IRR were similar regardless of prior rituximabexposure. Overall, the safety results such as SAEs and
serious infections were consistent with those reported
in 2 rituximab pivotal trials in patients who were antiTNF inadequate responders [1,3].
The safety and feasibility of shorter rituximab infusion
times have been evaluated in several published studies
[9-17]. In general, the safety of the faster infusion has
been reported in previously published studies to be comparable to that of the standard 4.25 hour infusion, and
the results of the present study confirm these findings.
Of note, in the oncology setting, a study called RATE
utilized a similar study design as the present RATE-RA
study [18]. These results supported a label change that
provides for an option for a faster infusion schedule of
rituximab from cycle 2 onward for patients with NHL
who tolerated their first rituximab infusion administered
at the standard rate. Given that patients with RA have a
lower baseline B cell count compared with patients with
lymphoma and generally tolerate the infusion better, patients in RATE-RA were expected to and did tolerate
the faster infusion rate, consistent with the results from
the oncology setting.
This was the first, large, prospective study to evaluate
the safety of a faster rate of rituximab in patients with RA.
External control incidences were calculated based on integrated data from the rituximab RA clinical development
program that used pooled data of all patients exposed to
rituximab (all-exposure population). The expected control
incidence was calculated based on historical incidences
weighted to account for patients with previous rituximab
treatment. These reference rates provide a more robust
comparison than IRR incidences found in the available
literature, which are limited by small or dissimilar patient populations. Because this study assessed the safety
of rapidly infused rituximab against the standard rituximab infusion rate, the lack of active comparators might
be considered a limitation.

Conclusions
In conclusion, this study demonstrated that rituximab can
be administered at the faster infusion rate at the second
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and subsequent infusions without increasing the risk or
severity of IRRs in patients with RA. As shorter infusion
times can improve not only patient satisfaction but also
infusion center efficiency, the results of this study provide
clinically relevant information for both health care providers and patients.
Competing interests
CP has received speaker fees from Genentech, Abbvie, Pfizer, BMS; MG has
received research grants from Genentech/Roche; JK has received research
grants from Genentech, Pfizer, UCB and Novartis and has received consulting
fees from BMS, Genentech, Pfizer, Lilly; NG has received research grants and
consulting fees from Genentech/Roche; WRigby has received consulting fees
from Roche Pharmaceuticals; SZ, CC and WReiss are employees of
Genentech Inc; BJ is an employee of Hoffmann-La Roche Ltd.
Authors’ contributions
CP, SZ, BJ and WReiss conceived and designed the research. All authors
made substantial contributions to the analysis and/or interpretation of the
data and to drafting and revising the manuscript. CC performed the
statistical analysis. All authors read and approved the final manuscript.
Acknowledgements
This study was sponsored and funded by Genentech and Biogen Idec.
Support for third-party writing assistance for this manuscript, furnished by
Vivian Chen, PharmD of Health Interactions, was provided by F. Hoffmann-La
Roche, Ltd.
Author details
1
Rheumatology Specialty Center, 2360 Maryland Road, Willow Grove, PA
19090, USA. 2Desert Medical Advances, Palm Desert, CA, USA. 3Albany
Medical College and the Center of Rheumatology, Albany, NY, USA. 4Arthritis
& Rheumatic Disease Specialties, Aventura, FL, USA. 5Geisel School of
Medicine at Dartmouth, Hanover, NH, USA. 6Genentech, Inc., South San
Francisco, CA, USA. 7F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Received: 29 January 2014 Accepted: 16 May 2014
Published: 24 May 2014
References
1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC,
Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T,
Totoritis MC, REFLEX Trial Group: Rituximab for rheumatoid arthritis
refractory to anti-tumor necrosis factor therapy: results of a multicenter,
randomized, double-blind, placebo-controlled, phase III trial evaluating
primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006,
54(9):2793–2806.
2. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados
M, Burmester GR, Greenwald M, Kvien TK, Williams S, Hagerty D, Cravets
MW, Shaw T: Rituximab inhibits structural joint damage in patients with
rheumatoid arthritis with an inadequate response to tumour necrosis
factor inhibitor therapies. Ann Rheum Dis 2009, 68(2):216–221.
3. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S,
Yin M, Kelman A: Efficacy and safety of retreatment in patients with
rheumatoid arthritis with previous inadequate response to tumor
necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol
2010, 37(5):917–927.
4. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K,
Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK,
Douglass W, Tyrrell H: Efficacy and safety of different doses and
retreatment of rituximab: a randomised, placebo-controlled trial in
patients who are biological naive with active rheumatoid arthritis and
an inadequate response to methotrexate (Study Evaluating Rituximab’s
Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010,
69(9):1629–1635.
5. Rituxan(r) [package insert]. South San Francisco, CA: Genentech, Inc; 2013.
6. Chung CH: Managing premedications and the risk for reactions to
infusional monoclonal antibody therapy. Oncologist 2008, 13(6):725–732.
7. Atmar J: Review of the safety and feasibility of rapid infusion of
rituximab. J Oncol Pract 2010, 6(2):91–93.

Pritchard et al. BMC Musculoskeletal Disorders 2014, 15:177
http://www.biomedcentral.com/1471-2474/15/177

8.

9.

10.
11.

12.

13.

14.

15.
16.
17.
18.

Page 9 of 9

van Vollenhoven RF, Emery P, Bingham CO, Keystone EC 3rd, Fleischmann
RM, Furst DE, Tyson N, Collinson N, Lehane PB: Long-term safety of
rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical
trial programme with a focus on adverse events of interest in RA
patients. Ann Rheum Dis 2013, 72(9):1496–1502.
Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B,
Souliere S, Spinelli JJ, Sutherland J, Connors JM: Rapid infusion rituximab in
combination with corticosteroid-containing chemotherapy or as
maintenance therapy is well tolerated and can safely be delivered in the
community setting. Blood 2007, 109(10):4171–4173.
Tuthill M, Crook T, Corbet T, King J, Webb A: Rapid infusion of rituximab
over 60 min. Eur J Haematol 2009, 82(4):322–325.
Can M, Alibaz-Oner F, Yilmaz-Oner S, Atagunduz P, Inanc N, Direskeneli H:
Accelerated infusion rates of rituximab are well tolerated and safe in
rheumatology practice: a single-centre experience. Clin Rheumatol 2013,
32(1):87–90.
Faraawi R, Roth K: Experience with accelerated rituximab infusion for
rheumatoid arthritis in a single community practice. Ann Rheum Dis 2010,
69(Suppl 3):383.
Bukh G, Larsen S, Rasmussen SS, Molgard MK, Hansen M: Accelerated
infusion rate of rituximab for rheumatoid arthritis is well tolerated and
safe. Arthritis Rheum 2008, 58(9, Suppl.):S857–S858.
Bukh G, Larsen SS, Rasmussen MS: Very fast infusion-rate of rituximab for
rheumatoid arthritis is well tolerated and safe. Ann Rheum Dis 2011,
70(Suppl III):754.
Larsen JL, Jacobsen S: Rapid infusion with rituximab: short term safety in
systemic autoimmune diseases. Rheumatol Int 2013, 33(2):529–533.
Schoeffel DA, Henn SM, Goedde A: Simplified treatment protocol of
rituximab in rheumatoid arthritis. Ann Rheum Dis 2008, 67(Suppl II):337.
Larsen JL, Jacobsen S: Rapid infusion with rituximab: short term safety in
systemic autoimmune diseases. Ann Rheum Dis 2010, 69(Suppl III):731.
Dakhil S, Hermann R, Chai A, Hurst D, Fine G, Richards P: Final results of a
single arm phase Ill multicenter, open-label study of rituximab administered
by faster infusion in patients with previously untreated diffuse large B-cell
(DLBCL) or follicular non-Hodgkin’s lymphoma (FL) [abstract]. In Presented at:
53rd American Society of Hematology (ASH) Annual Meeting and Exposition;
December 10–13, 2011; San Diego, CA Abstract #2703.

doi:10.1186/1471-2474-15-177
Cite this article as: Pritchard et al.: Safety of infusing rituximab at a more
rapid rate in patients with rheumatoid arthritis: results from the RATERA study. BMC Musculoskeletal Disorders 2014 15:177.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

